npj Precision Oncology is a new open-access journal committed to publishing cutting edge scientific research in all aspects of precision oncology from basic science to translational applications, to clinical medicine.
npj Precision Oncology volume 7, Article number: 134 (2023) Cite this article 2886 Accesses 1 Citations Metrics details Abstract We aimed to apply a potent deep learning network, NAFNet, to predict adverse pathology events and biochemical recurrence-free survival (bRFS) based on pre-treatment ...
New modalities for deep measurement of disease and precision oncology therapeutics represent a potential “sea change” transition point for precision oncology. The first “wave” included the development of symbolic artificial intelligence tools (1997, Deep Blue expert system beat Kasparov in chess; 201...
The immunosuppressive tumor microenvironment (TME) in PDAC, a major factor contributing to immunotherapy resistance, includes tumor-infiltrating immune-suppressive cells, stromal cells, the microbiome, and the extracellular matrix (ECM). The immune infiltration in PDAC is characterized by an abundance of ...
documents published in that journal. The chart shows the evolution of the average number of times documents published in a journal in the past two, three and four years have been cited in the current year. The two years line is equivalent to journal impact factor ™ (Thomson Reuters) ...
Opportunities and challenges for patient-derived models of brain tumors in functional precision medicine Mann, Breanna;Artz, Nichole;Darawsheh, Rami;Kram, David E.;Hingtgen, Shawn;Satterlee, Andrew B. 2025npj Precision Oncology doi:10.1038/s41698-025-00832-wpmid:39953052 ...
2022npj Precision Oncology doi:10.1038/s41698-022-00254-ypmid:35228642 Patients with advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer who are prescribed ALK-tyrosine kinase inhibitors (ALK-TKIs) rarely have complete responses, with residual tumors relapsing as heterogeneous...
documents published in that journal. The chart shows the evolution of the average number of times documents published in a journal in the past two, three and four years have been cited in the current year. The two years line is equivalent to journal impact factor ™ (Thomson Reuters) ...
Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology Article Open access 27 October 2022 Magnitude of effect and sample size justification in trials supporting anti-cancer drug approval by the US Food and Drug Administration Article Open access ...
Tumor drug resistance emerges from the interaction of two critical factors: tumor cellular heterogeneity and the immunosuppressive nature of the tumor microenvironment (TME). Tumor-associated macrophages (TAMs) constitute essential components of the TME.